Short Interest in Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Expands By 483.1%

Key Points

• Short interest in Shionogi & Co., Ltd. increased dramatically by 483.1%, totaling 304,400 shares as of August 31, up from 52,200 shares on August 15.
• The company's stock price is currently around $9.05, with a market capitalization of $15.40 billion and a P/E ratio of 15.29.
• Shionogi reported earnings of $0.16 EPS for the last quarter, exceeding expectations and indicating revenue of $672.90 million, which was lower than anticipated.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 304,400 shares, a growth of 483.1% from the August 15th total of 52,200 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 146,300 shares, the days-to-cover ratio is presently 2.1 days. Based on an average trading volume of 146,300 shares, the days-to-cover ratio is presently 2.1 days. Currently, 0.0% of the shares of the company are sold short.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

Shares of SGIOY stock traded up $0.01 during trading hours on Wednesday, reaching $8.90. The stock had a trading volume of 3,953 shares, compared to its average volume of 103,026. The stock's fifty day simple moving average is $8.70 and its 200 day simple moving average is $8.30. The firm has a market capitalization of $15.14 billion, a PE ratio of 15.26, a PEG ratio of 2.03 and a beta of 0.20. Shionogi & Co., Ltd. Unsponsored ADR has a 12 month low of $6.53 and a 12 month high of $9.23. The company has a current ratio of 6.63, a quick ratio of 6.13 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.02. The company had revenue of $672.90 million for the quarter, compared to the consensus estimate of $719.55 million. On average, equities research analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 EPS for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.